Navigation Links
Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
Date:10/25/2007

ed by the European Organization for Research and Treatment of Cancer (EORTC).

Brostallicin was discovered at Pharmacia and developed by Nerviano Medical Sciences (NMS) the largest pharmaceutical research and development facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Following a merger between Pfizer and Pharmacia, the rights to brostallicin were assigned to NMS which continued its development and ultimately licensed worldwide rights to Systems Medicine.

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately-held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's context of vulnerability. Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs -- the context of vulnerability.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of our bis-platinate drug candidates, CT-47613 and CT-47609 include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with our bis-platinate drug candidates in particular including, without limitation, th
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2008)...all/ -- Neuralstem Inc.,(Amex: CUR ) today annou...ntions from Cleveland Clinic pertaining to Targete...entions were developed by Dr. Nicholas,Boulis MD, ...ity., (Logo: http://www.newscom.com/cgi-bin/prnh... have licensed-in these important delivery,technol...
(Date:10/14/2008)...armaceuticals, Inc. today,announced the Company,s ...irst-in-class aminomethylcycline, will be the subj...8th Interscience Conference on Antimicrobial,Agent...Washington, D.C.,from October 25 - October 28, 200...AC:, Sunday, October 26, 12:15 - 1:15 pm EST ...
(Date:10/14/2008)...ing 12-Month Outcomes from, Single- Center Study I...ns, WASHINGTON, Oct. 14 /- OrbusNeic...onth follow-up data from the global e-HEALING,regi...ld use of the,company,s Genous Bio-engineered R st....D., Ph.D., of the Academic,Medical Center in Amst...
(Date:10/13/2008)...g advances study Study needed because of low... 13 /- Advanced Circulatory Systems, ...ced today that it has received,an additional $1.5 ...,Health (NIH) to continue a study testing two devi...rdiac arrest outside a hospital. Whatcom County, W...
Breaking Medicine Technology:Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 2Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 3Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 11031 1Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 11031 2Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management 11031 3Ingenious Med Reports Record Sales and Client Expansions in 2007 11028 1Ingenious Med Reports Record Sales and Client Expansions in 2007 11028 2Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 1Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 2Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 3Consumer Reports Poll 3A Americans Demand Health Reform But Are Unsure About How to Achieve it 11025 4Halogen Receives High Ratings from Bersin 26 Associates Company recognized as a market leader and receives praise for outstanding customer satisfa 3031 1Halogen Receives High Ratings from Bersin 26 Associates Company recognized as a market leader and receives praise for outstanding customer satisfa 3031 2
...in-human results for,IMC-A12, a monoclonal antibod...Q: IMCL) and targeted to IGF-1R (insulin-like,grow...annual,meeting of the American Society of Clinical...he cell surface of must human cancers,and transmit...feration, and inhibition of programmed cell death....
...- Elixir,Pharmaceuticals, Inc., announced today ne...s a potential method for regulating,metabolism, de...he,data were presented in poster sessions during E...g, being held in Toronto,Canada. Elixir is focuse... metabolic disease, as well as prevent age-related...
Other Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4
(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
...t patients who develop Parkinson's disease in yout...cohol// abuse may be more likely to develop pathol...ed to treat their condition. Behaviors associated...sive shopping, hypersexuality, binge eating and pa...
... sclerosis (MS) for 10 years and have few of the d...ey// have “benign MS” and that their symptoms will... people with MS. A new study shows that unfortunat...0 years, the disease had progressed in nearly half...
...ge for colorectal cancer screening has increased, ...ng// practices. According to a report published re..., sex, age, education and income levels. Colorec...ncer affecting men and women in the United States ...
... a powerful two-gene test that can distinguish bet... cancers that require radically different courses ... in the online Early Edition of the Proceedings of...iences. "This simple and accurate test has the po...
Other Medicine News:Health News:Compulsive Gambling Linked to Parkinson's Disease Medications 2Health News:Disparities in Colon Cancer Screening Remain Among Medicare Patients 2Health News:A New Two-gene Test to Discern Similar Gastrointestinal Cancers 2
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
Medicine Products: